GO
Loading...

Enter multiple symbols separated by commas

Stocks Pfizer Inc

More

  • July 13- Drug developer Anacor Pharmaceuticals Inc said data showed its experimental ointment to treat an itchy skin condition met the main goal of late-stage studies, sending its shares up more than 50 percent. The condition affects about 9-30 percent of the U.S. population, according to the National Institutes of Health. Other companies developing a...

  • Study links Prozac, Paxil use with birth defects Thursday, 9 Jul 2015 | 5:18 PM ET

    July 9- A sweeping government study of thousands of women has found links between the older antidepressants Prozac and Paxil and birth defects, but has cleared other popular treatments in the class, including Celexa, Lexapro and Pfizer's Zoloft, which is the subject of a major lawsuit over birth defect claims. Earlier studies had raised questions about...

  • For US soccer wages, it's still a man's game Monday, 6 Jul 2015 | 3:12 PM ET
    Carli Lloyd of the United States reacts in the first half after scoring a goal against Japan in the FIFA Women's World Cup Canada 2015 Final at BC Place Stadium on July 5, 2015, in Vancouver, British Columbia.

    Even with their World Cup victory, U.S. women's soccer players will have a tough time converting success into financial gains.

  • Pfizer Inc, the largest U.S. drugmaker, for example reported more than $234.2 million in research payments and another $53.3 million in general payments. John Diliberti, a pediatric geneticist from Illinois, collected nearly $447,000 from Pfizer in consulting fees last year, the biggest single payment to an individual doctor by the drugmaker.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks plunged nearly 2 percent or more, with the Dow wiping out gains for the year on escalating tensions between Greece and its creditors.

  • BASEL, Switzerland, June 29- Drugmakers said on Monday they would continue to ship medicines to Greece in coming weeks, despite mounting unpaid bills, but warned supplies could be in jeopardy if Europe did not take emergency action. A copy of the letter to EU Health Commissioner Vytenis Andriukaitis from Richard Bergstrom, director general of the European...

  • June 26- Drug developer Celladon Corp said on Friday it may liquidate itself if it were unable to find a buyer, and was suspending development of its gene therapy for heart failure. Celladon said if it were to liquidate during the third quarter ending September, the net cash available for distribution to shareholders would be about $25 million- $30 million.

  • June 25- Canada- based drugmaker Valeant Pharmaceuticals International Inc has approached to buy Zoetis Inc, an animal-health company, the Wall Street Journal reported. Shares of Zoetis, whose pipeline includes medicines and vaccines for pets and livestock, were up 2 percent at $56.65 in extended trading. The decision came a month after Bill Ackman's Pershing...

  • Valeant offers to buy Zoetis - WSJ Thursday, 25 Jun 2015 | 4:30 PM ET

    June 25- Canada- based drugmaker Valeant Pharmaceuticals International Inc has approached to buy Zoetis Inc, an animal-health company, the Wall Street Journal reported. Zoetis, spun off from Pfizer Inc in 2013, was valued at $24.85 billion as of Thursday's close, according to Thomson Reuters data. It was not clear what Zoetis's reaction to the approach was, if any,...

  • Zoetis halted for volatility on takeover report Thursday, 25 Jun 2015 | 3:58 PM ET
    Zoetis

    Animal health behemoth Zoetis was halted for volatility on Thursday.

  • America's top states for innovation in 2015 Wednesday, 24 Jun 2015 | 4:30 PM ET
    Top States Technology and Innovation

    These 10 states lead the nation in tech investment, patents and research, which has helped reinvigorate their local economies.

  • Traders see money in this drug stock Wednesday, 24 Jun 2015 | 1:46 PM ET
    People walk past Pfizer world headquarters in New York City.

    Investors are flocking to health-care stocks, and one trader is betting on big returns from drug company Pfizer.

  • *Fast-track legislation clears Senate procedural hurdle. *Senate vote of 60-37 shows solid support base. On Wednesday, the Senate was likely to vote to grant Obama the power to speed trade deals through Congress, including his Trans-Pacific Partnership.

  • Two big problems with generic-drug substitution Tuesday, 23 Jun 2015 | 3:54 PM ET
    Pharmaceutical drugs

    Automatic generic-drug substitution poses several big problems, says NYU Professor Melissa Schilling.

  • Senate vote of 60-37 shows solid support base. WASHINGTON, June 23- President Barack Obama's quest for a Pacific Rim trade deal to strengthen U.S. ties with Asia advanced on Tuesday, with the Senate moving toward a final vote on granting Obama the power to speed trade agreements through Congress. That just barely satisfied the 60- vote threshold needed after two...

  • *Senate vote 60-37 shows solid support base. WASHINGTON, June 23- President Barack Obama's Pacific Rim trade pact moved closer to a final U.S. Congress vote, with lawmakers agreeing on Tuesday to limit debate on legislation that would grant Obama authority to speed trade deals through Congress. A Senate vote on the legislation, known as fast-track negotiating...

  • Uncertainty for stocks remains. What to buy Tuesday, 23 Jun 2015 | 8:00 AM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stocks could be in for a bumpy ride this summer as concerns over Greece's debt situation mount. Here's how to play it.

  • President Barack Obama' s signature Pacific trade pact faces another test in the Senate on Tuesday as legislation needed to close the deal returns for a second run through the chamber. Although the measure passed the Senate a month ago on a vote of 62-37, including backing from 14 Democrats, some may withdraw support. It took two attempts to pass this same...

  • Early movers: CI, WMB, PFE, ALL, AAPL & more Monday, 22 Jun 2015 | 7:47 AM ET
    Traders work on the floor of the New York Stock Exchange (NYSE).

    Some of the names on the move ahead of the open.

  • LONDON, June 22- GlaxoSmithKline has agreed to sell two meningitis vaccines to Pfizer to satisfy antitrust concerns after its recent acquisition of vaccines business of Novartis. The British drugmaker said on Monday that the total consideration for the sale of its Nimenrix and Mencevax products to Pfizer's Irish unit, including some deferred payments, was...